In a notable rebound on June 12th, the A-share and H-share innovative drug sectors demonstrated significant strength. The Huabao Pharmaceutical ETF (562050), heavily weighted in A-share innovative drug stocks, and the Huabao Hong Kong Stock Connect Innovative Drug ETF (520880), fully invested in Hong Kong pharmaceutical shares, both posted substantial gains.
The A-share pharmaceutical sector saw a sharp upward move before noon. The Huabao Pharmaceutical ETF (562050), the sole exchange-traded fund tracking the pharmaceutical sector, climbed as much as 2.35%, successfully reclaiming its 10-day moving average. Constituent stocks such as Baili Tianheng, Hansoh Pharma, and Apeloa Pharmaceutical all rose over 5%.
The Hong Kong Stock Connect innovative drug segment exhibited even greater elasticity. The Huabao Hong Kong Stock Connect Innovative Drug ETF (520880), which invests 100% in innovative drug R&D targets, surged nearly 4% intraday. Trading volume spiked sharply, with turnover reaching 3.93 billion yuan by the time of writing, already surpassing the previous day's full-day total.
Leading heavyweight stocks in the innovative drug sector were all in positive territory. Innovent Biologics rose over 4%, while Akeso, Sino Biopharmaceutical, and Kelun-Botech advanced more than 5% and 7%, respectively.
A recent industry weekly report from Industrial Securities, dated June 10th, suggests the innovative drug sector is gradually shifting from being driven by "valuation" to being driven by "earnings + global realization." The execution of Business Development (BD) transactions over the past two years marks the first step for overseas expansion. Subsequent progress in overseas Phase III clinical trials, increased certainty of product approval, and the realization of commercialization revenue sharing will serve as significant catalysts for products already involved in BD deals. These developments are expected to further enhance the potential peak sales and success rates of these products. Looking ahead, clinical data presentations at industry conferences, major BD transactions, and breakthroughs in new technologies are anticipated to continue providing positive catalysts.
For investors looking to position in the innovative drug rebound at lower levels, two key investment tools are highlighted.
For a pure play on innovative drugs, consider the Huabao Hong Kong Stock Connect Innovative Drug ETF (520880). It offers 100% exposure to companies engaged in innovative drug R&D, with its top ten holdings accounting for over 70% of the portfolio, highlighting its focus on sector leaders. Its underlying assets are Hong Kong-listed stocks, offering high elasticity and T+0 settlement.
For those seeking to reduce volatility, the Huabao Pharmaceutical ETF (562050) is the only such fund available in the market. It features a unique allocation of "70% innovative drugs + 30% traditional Chinese medicine," making it a scarce investment product that combines the high growth potential of innovative drugs with the high dividend characteristics of traditional Chinese medicine stocks.
Data is sourced from the Shanghai, Shenzhen, and Hong Kong stock exchanges, China Securities Index Co., Ltd., and Hang Seng Indexes Company.
Note: ETF funds do not charge sales service fees. When investors subscribe for or redeem fund units, the subscription/redemption agent may charge a commission of up to 0.5%, which includes related fees charged by the stock exchange and registration institutions. Please refer to each fund's legal documents for detailed fee structures.
Risk Disclosure: The index constituent stocks mentioned are for illustrative purposes only. Descriptions of individual stocks are not intended as investment advice in any form and do not represent the holdings or trading activities of any fund managed by the fund manager. The fund manager assesses the risk rating of the Huabao Pharmaceutical ETF and its feeder fund as R3 (Medium Risk), suitable for Balanced (C3) and higher risk-tolerance investors. The risk rating for the Huabao Hong Kong Stock Connect Innovative Drug ETF and its feeder fund is assessed as R4 (Medium-High Risk), suitable for Aggressive (C4) and higher risk-tolerance investors. Any information appearing in this article (including but not limited to individual stocks, commentary, forecasts, charts, indicators, theories, or any form of expression) is for reference only. Investors are responsible for their own investment decisions. Furthermore, any views, analysis, or predictions herein do not constitute investment advice of any kind to the reader, and no liability is accepted for any direct or indirect losses arising from the use of this content. The performance of other funds managed by the fund manager does not guarantee the performance of these funds. Past performance of a fund is not indicative of its future results. Fund investment carries risks.
A MACD golden cross signal has formed, indicating positive momentum for these stocks.
Comments